EPIDAREX ANNOUNCES LEADERSHIP APPOINTMENTS
July 22, 2026
With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen
With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen
Round includes participation from Medtronic and top healthcare investors MIAMI, July 16, 2026 (GLOBE NEWSWIRE) — RapidPulse, Inc., a medical technology company developing next-generation aspiration
Data published in the Journal of the American College of Cardiology Represents first peer-reviewed publication of clinical data demonstrating reductions in cardiometabolic risk markers with
Boston, MA, May 19, 2026 – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory
ATLANTA, May 14, 2026 /PRNewswire/ — Nyra Medical, a leading innovator in structural heart therapies, today announced its participation in the upcoming EuroPCR meeting, where the company
Brighton, UK, 12 May 2026: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives
· OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancer · Recruitment on track in OCTOPOD-IV,
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies
Edinburgh, UK – 19 February 2026 – Lario Therapeutics (“Lario” or the “Company”), a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders,
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled upregulation of FAN1, a genetically validated target in Huntington’s disease Clinical Advisory Board